Want to see IN:TATVA full AI Analyst Report?
TATVA Stock Chart & Stats
₹1388.35
-₹14.30(-1.60%)
At close: 4:00 PM EST
₹1388.35
-₹14.30(-1.60%)
Day’s Range― - ―
52-Week Range₹1,045.70 - ₹2,109.95
Previous CloseN/A
Volume13.99K
Average Volume (3M)5.36K
Market Cap
₹44.03B
Enterprise Value₹43.23B
Total Cash (Recent Filing)₹87.91M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)70.3
Beta1.11
Next Earnings
Jan 21, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.11%
Share Statistics
EPS (TTM)21.97
Shares Outstanding23,392,056
10 Day Avg. Volume7,143
30 Day Avg. Volume5,362
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.15
Price to Sales (P/S)4.87
P/FCF Ratio-29.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)30.2
Revenue Forecast (FY)₹6.39B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA large equity base relative to debt indicates modest leverage and meaningful financial flexibility. The improvement from historically higher leverage should help Tatva fund operations and withstand uneven industry conditions over the next several quarters.
Revenue RecoveryThe FY2026 revenue rebound shows renewed demand across Tatva’s specialty-chemical activities after a period of contraction. If sustained, stronger volumes can improve fixed-cost absorption, support customer relationships, and provide a foundation for earnings recovery.
Diversified Specialty-chemical PortfolioTatva supplies SDPTCs, quaternary ammonium salts, specialty chemicals, and electrolyte salts across several end markets. This breadth can reduce dependence on any single application and supports recurring industrial demand where consistent, compliant supply is required.
Bears Say
Persistently Negative Free Cash FlowPersistently negative free cash flow weakens the quality of reported earnings because growth and operations are not consistently converting into cash. Continued reinvestment or working-capital needs could increase reliance on the balance sheet and limit financial flexibility.
Volatile Earnings ProfileLarge swings in operating profit and net income indicate uneven cost and pricing dynamics. Although FY2026 improved from a low base, earnings remain below earlier peaks, making future profitability less predictable and weakening confidence in a durable recovery.
Recent Debt IncreaseThe FY2026 increase in debt is a developing balance-sheet risk even though leverage remains modest overall. If returns and cash generation do not continue to recover, higher borrowings could reduce flexibility and add pressure to future capital allocation.
Tatva Chintan Pharma Chem Limited News
TATVA FAQ
What was Tatva Chintan Pharma Chem Limited’s price range in the past 12 months?
Tatva Chintan Pharma Chem Limited lowest stock price was ₹1045.70 and its highest was ₹2109.95 in the past 12 months.
What is Tatva Chintan Pharma Chem Limited’s market cap?
Tatva Chintan Pharma Chem Limited’s market cap is ₹44.03B.
When is Tatva Chintan Pharma Chem Limited’s upcoming earnings report date?
Tatva Chintan Pharma Chem Limited’s upcoming earnings report date is Jan 21, 2027 which is in 91 days.
How were Tatva Chintan Pharma Chem Limited’s earnings last quarter?
Tatva Chintan Pharma Chem Limited released its earnings results on Oct 19, 2026. The company reported ₹9.7 earnings per share for the quarter, beating the consensus estimate of ₹7.1 by ₹2.6.
Is Tatva Chintan Pharma Chem Limited overvalued?
According to Wall Street analysts Tatva Chintan Pharma Chem Limited’s price is currently Overvalued.
Does Tatva Chintan Pharma Chem Limited pay dividends?
Tatva Chintan Pharma Chem Limited pays a Annually dividend of ₹2 which represents an annual dividend yield of 0.11%. See more information on Tatva Chintan Pharma Chem Limited dividends here
What is Tatva Chintan Pharma Chem Limited’s EPS estimate?
Tatva Chintan Pharma Chem Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tatva Chintan Pharma Chem Limited have?
Tatva Chintan Pharma Chem Limited has 23,392,056 shares outstanding.
What happened to Tatva Chintan Pharma Chem Limited’s price movement after its last earnings report?
Tatva Chintan Pharma Chem Limited reported an EPS of ₹9.7 in its last earnings report, beating expectations of ₹7.1. Following the earnings report the stock price went down -2.079%.
Which hedge fund is a major shareholder of Tatva Chintan Pharma Chem Limited?
Currently, no hedge funds are holding shares in IN:TATVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited, an Indian-based enterprise, specializes in the production and distribution of diverse specialty chemicals. Its extensive product range encompasses essential components like structure-directing agents crucial for zeolite synthesis, phase transfer catalysts, and electrolyte salts vital for supercapacitor batteries. Furthermore, the company supplies pharmaceutical active pharmaceutical ingredients (APIs), agrochemical formulations, and various other specialized chemical products, including intermediates, disinfectants, catalytic agents, and solvents. Beyond manufacturing, Tatva Chintan engages in the trading of specialty chemicals and offers quaternary compounds (quats) and bulk drug substances. The firm's clientele spans a broad spectrum of sectors, such as the automotive, petrochemical, pharmaceutical, agricultural chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrance industries. Its global reach extends to approximately 25 nations, where its products are exported. Established in 1996, Tatva Chintan Pharma Chem Limited maintains its corporate headquarters in Vadodara, India.
Technical Analysis
AARTI Industries Ltd
―
Alkyl Amines Chemicals Limited
―
Jubilant Ingrevia Ltd.
―
Rossari Biotech Ltd
―
Vinati Organics Limited
―